OA
EGRX

Oak Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Oak Associates’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,125
Closed -$966K – 137
2020
Q2 		$966K Hold
20,125
– – 0.06% 96
2020
Q1 		$926K Sell
20,125
-60
-0.3% -$3.01K 0.08% 90
2019
Q4 		$1.21M Hold
20,185
– – 0.07% 101
2019
Q3 		$1.14M Hold
20,185
– – 0.07% 97
2019
Q2 		$1.12M Buy
20,185
+11,965
+146% +$624K 0.07% 100
2019
Q1 		$415K Hold
8,220
– – 0.03% 137
2018
Q4 		$331K Hold
8,220
– – 0.02% 146
2018
Q3 		$570K Hold
8,220
– – 0.03% 133
2018
Q2 		$622K Hold
8,220
– – 0.04% 120
2018
Q1 		$433K Buy
+8,220
New +$478K 0.03% 136

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oak Associates's EGRX Position: Q3 2020 in Review

Oak Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 20,125 shares — an estimated $966K sold.

Oak Associates first reported a position in EGRX in Q1 2018 and held it in 10 quarters. The position peaked at $1.21M in Q4 2019. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • Oak Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Oak Associates sold 20,125 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $966K.
  • Oak Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 10 quarters.
  • Oak Associates's Eagle Pharmaceuticals, Inc. position peaked at $1.21M in Q4 2019.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on Oak Associates's 13F filing for Q3 2020, filed 13 Nov 2020.